Company intelligence / Profile preview
Celosia Therapeutics
Macquarie Park, New South Wales, Australiacelosiatx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Celosia Therapeutics is developing CTx1000, a novel gene therapy targeting TDP-43 protein for ALS. The groundbreaking discovery was published in the journal Neuron in February 2024. The company is advancing toward clinical trials after securing significant Series A funding.
- Therapeutic areas
- Neurology
- Modalities
- Gene therapy
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Celosia Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Celosia Therapeutics.